Knowledge Ecology International

Australia, the European Union, Japan, Switzerland, Chinese Taipei and the United States requested the Secretariat of the World Trade Organization (WTO) to place an item on the agenda of the November 2016 TRIPS Council agenda entitled – “Intellectual Property and Innovation: Regional Innovation Models. On 9 November 2016, the European Union delivered the following intervention on regional innovations models. Intellectual Property and Innovation have been on the agenda of the TRIPS Council since 2012.

IP AND INNOVATION: REGIONAL INNOVATION MODELS

Continue Reading →

Updated
According to this story, the India Patent Office has denied a patent for the prostate cancer drug sold under the brand name Xtandi (generic name Enzalutamide). Opponents of the patent claimed it was a new form of a known substance, and not eligible in India under Section 3(d) of its patent act.

Continue Reading →

Today The Lancet Commission on Essential Medicines Policies published the 74 page report on “Essential Medicines for Universal Health Coverage.” A copy is available here.

The report is rich in data, analysis and recommendations. The report endorses the delinking of R&D costs from drug prices:

Delinking R&D costs from the price of medicines

Continue Reading →

KEI and others working in the drug pricing space are frequently asked about measures that a new President or Congress can take to lower drug prices, in the relatively near term. The following is a list of such actions, including some that would require legislation and some that would not.

A comprehensive list of possible actions would be much longer, and this is not such a list. Our list does not include suggestions from several other groups working on drug pricing that deserve consideration, and there is nothing at this point on price spikes.

Continue Reading →